-

01:15:45 PM

PRTK Stock News

PRTK - Paratek Pharmaceuticals Inc.

09/21/23 8:58 AM

Nasdaq : PRTK

acquisition

Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.

Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. (“Paratek” or the “Company”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical

RHEA-AI

neutral

09/18/23 9:37 AM

Nasdaq : PRTK

acquisition

Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S

Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced,

RHEA-AI

neutral

09/12/23 7:30 AM

Nasdaq : PRTK

acquisition

Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S

Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for

RHEA-AI

neutral

09/07/23 3:34 PM

Nasdaq : PRTK

acquisition

Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings

Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that

RHEA-AI

neutral

08/03/23 8:00 AM

Nasdaq : PRTK

earnings

Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million

Previously Announced Agreement to be Acquired by Gurnet Point Capital and Novo Holdings A/S; Transaction Expected to Close in the Third Quarter BOSTON, Aug. 03,

RHEA-AI

neutral

08/02/23 5:36 PM

Nasdaq : PRTK

acquisition

Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings

Transaction Provides Paratek Stockholders with Immediate Value and Liquidity Stockholders to Receive Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 per Share on Achievement of a Commercial Milestone for a Total Potential Value of $3.00 per Share Special Meeting of

RHEA-AI

neutral

07/11/23 4:15 PM

Nasdaq : PRTK

acquisition

NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point Capital

NexPoint Event Driven Fund today issued a demand letter to the Board of Directors of Paratek Pharmaceuticals, Inc. to make available all books and records surrounding the proposed acquisition of the Company in order to investigate whether any...

RHEA-AI

neutral

07/10/23 8:00 AM

Nasdaq : PRTK

Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical

RHEA-AI

neutral

06/27/23 12:01 PM

Nasdaq : PRTK

Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter

Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today acknowledged

RHEA-AI

neutral

06/27/23 8:00 AM

Nasdaq : PRTK

acquisition

NexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point Capital

NexPoint Asset Management, L.P., together with its affiliates, who beneficially own approximately 12% of the outstanding common stock of...

RHEA-AI

negative

1 2 3 4 5 6 7 8 9 10 Next

PRTK Data

IndustryPharmaceutical Preparation Manufacturing
Websitehttp://paratekpharma.com/
Security nameParatek Pharmaceuticals Inc.
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
CountryUS

About Paratek Pharmaceuticals Inc.

paratek pharmaceuticals (nasdaq: prtk) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. we focus on drugs that target infectious disease and other difficult to treat conditions. our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against gram-positive, gram-negative and atypical bacteria. omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. the food and drug administration (fda) granted omadacycline a qualified infectious disease product (qidp) designation and completed two special protocol assessments for its phase 3 clinical trial program.